Carrick Therapeutics was launched in 2016 with the aim of building the leading European based oncology company with a world class innovative R&D pipeline focusing on targeting key pathways in cancer progression and adaptive resistance.
LEADERSHIP
BOARD OF DIRECTORS & OBSERVERS
Carrick Therapeutics’ Board of Directors combines expertise from the pharmaceutical industry and the investment community with the shared goal of improving the lives of cancer patients.
SCIENTIFIC ADVISORY BOARD
Carrick Therapeutics is collaborating with world-class cancer researchers from Cambridge, Oxford, London, and Ireland to defeat cancer.
Sir John Bell
Chairman of Scientific Advisory Board, Carrick Therapeutics
University of Oxford
Professor Chas Bountra
University of Oxford
Professor Johann DeBono
Royal Marsden Hospital
Professor William Gallagher
University College Dublin
Professor Steve Jackson
University of Cambridge
Professor Peter Johnson
University of Southampton
Professor David Kerr
University of Oxford
Professor Michael O’Dwyer
National University of Ireland (Galway)
Doctor Anthony Quinn
Boston
Professor John Robertson
University of Nottingham
